A Phase 2, Open-Label, Single-Arm Study of Pamiparib (BGB-290) for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Homologous Recombination Deficiency (HRD) (Beigene)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
BeiGene, Ltd
Start Date
January 23, 2020
End Date
September 30, 2020
Administered By
Duke Cancer Institute
Awarded By
BeiGene, Ltd
Start Date
January 23, 2020
End Date
September 30, 2020